In vitro susceptibility of fungal and yeast clinical isolates to itraconazole and voriconazole (Q46656034)

24 December 2017

title

In vitro susceptibility of fungal and yeast clinical isolates to itraconazole and voriconazole (English)

1 reference

24 December 2017

author name string

Yolanda Morera-López

series ordinal

1

1 reference

24 December 2017

Josep Maria Torres-Rodríguez

series ordinal

2

1 reference

24 December 2017

Teresa Jiménez-Cabello

series ordinal

3

1 reference

24 December 2017

language of work or name

non-English

0 references

publication date

1 June 2005

1 reference

24 December 2017

Revista iberoamericana de micologia

published in

1 reference

24 December 2017

volume

22

1 reference

24 December 2017

issue

2

1 reference

24 December 2017

page(s)

105-109

1 reference

24 December 2017

Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2805%2970018-8

7 January 2021

Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2805%2970018-8

7 January 2021

In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2805%2970018-8

7 January 2021

In vitro susceptibilities of zygomycetes to conventional and new antifungals

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2805%2970018-8

7 January 2021

In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2805%2970018-8

7 January 2021

In vitro testing of Aspergillus fumigatus clinical isolates for susceptibility to voriconazole, amphotericin B and itraconazole: comparison of sensititre versus NCCLS M38-A using two different inocula

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2805%2970018-8

7 January 2021

Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2805%2970018-8

7 January 2021

[In vitro activity of amphotericin B, itraconazole and voriconazole against 20 species of Aspergillus using the Sensititre microdilution method].

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2805%2970018-8

7 January 2021

In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2805%2970018-8

7 January 2021

Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2805%2970018-8

7 January 2021

Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2805%2970018-8

7 January 2021

Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2805%2970018-8

7 January 2021

In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2805%2970018-8

7 January 2021

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2805%2970018-8

7 January 2021

Resistance of Candida species to fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2805%2970018-8

7 January 2021

In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2805%2970018-8

7 January 2021

In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2805%2970018-8

7 January 2021

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2805%2970018-8

7 January 2021

Susceptibility of Pseudallescheria boydii and Scedosporium apiospermum to new antifungal agents.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-1406%2805%2970018-8

7 January 2021

10.1016/S1130-1406(05)70018-8

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017